ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive
ClearPoint Neuro’s stock has delivered dramatic gains in 2025, transforming from a little-known small-cap into a high-flyer. The share price rallied over 300% from 2024 lows, driven by positive news in both the company’s own product line and its partners’ clinical trial successes. Notably, CLPT climbed from roughly $5.50 in May 2024 to over $19 by February 2025nasdaq.com. After a mid-year breather, momentum returned in Q3/Q4 2025: the stock surged nearly 40% in one day on September 24, 2025 after announcing an FDA clearance and bullish revenue guidancenasdaq.comnasdaq.com. By late October, ClearPoint hit new highs around $30, before settling in the mid-$20s as of early Novembermarketbeat.commarketbeat.com. This volatility reflects increasing trading activity and investor attention. Daily volumes have spiked during news events – for example, nearly 916,000 shares traded around late October when the stock jumped, far above normal levelsstockanalysis.com. The stock’s 50-day average price is now well above its 200-day averagedirectorstalkinterviews.com, confirming a strong uptrend through much of 2025. However, recent swings also underscore risk: on October 30, 2025, CLPT slid about 10% in one day to ~$24marketbeat.com, potentially as investors took profits ahead of earnings or reacted to broader market turbulence. Overall, volatility is high – the 52-week
